Drugs / DOC1021
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07288112 | Apr 2026 → Jan 2031 expected | — | Diakonos Oncology Corporation | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06805305 | Mar 2025 → Mar 2030 expected | glioblastoma | Diakonos Oncology Corporation | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DOC1021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07288112 ↗ |
| Known as | dubodencel | “DOC1021 (dubodencel), a novel DC vaccine regimen integrated with SOC.” PMID 41959823 ↗ Apr 2026 |
| Modality | Vaccine | “Double-loaded dendritic cell vaccine, loaded with tumor lysate and mRNA using proprietary method” NCT06805305 ↗ |
| Route | Other | “Undergo ultrasound guided perinodal DOC1021 injections every 2 weeks for a total of 3 doses” NCT06805305 ↗ |